ROCKET AF: Study Design Rivaroxaban 20 mg daily (15 mg for Cr Cl 30-49 ml/min) Warfarin INR target: 2.5 (2.0-3.0 inclusive) Primary Endpoint: Stroke or non-CNS Systemic Embolism Atrial Fibrillation Randomize Double Blind / Double Dummy (N= 14,264) Monthly Monitoring Adherence to standard of care guidelines Risk Factors, at least 2 of: CHF Hypertension Age  75 Diabetes OR Stroke, TIA or systemic embolus MR Patel et al.N Engl J Med 2011;365:883-91.
{}